Group 1 - BioLife Solutions, Inc. (BLFS) is a notable stock within the Medical sector, currently ranked 2 in the Zacks Sector Rank, which includes 1010 companies [2][3] - The Zacks Consensus Estimate for BLFS' full-year earnings has increased by 31.5% in the past quarter, indicating improved analyst sentiment and earnings outlook [4] - Year-to-date, BLFS has returned approximately 7.2%, outperforming the Medical group average loss of about 2.1% [4] Group 2 - BioLife Solutions, Inc. is part of the Medical - Products industry, which consists of 82 stocks and is currently ranked 139 in the Zacks Industry Rank, with an average gain of 19% this year [6] - In comparison, Ginkgo Bioworks Holdings, Inc. (DNA) has returned 34.2% year-to-date and is part of the Medical - Biomedical and Genetics industry, which has seen a decline of 10.3% [5][6] - Investors should monitor both BioLife Solutions, Inc. and Ginkgo Bioworks Holdings, Inc. for potential continued strong performance in the Medical sector [7]

Core Viewpoint - The article emphasizes the importance of identifying and maintaining stock price trends for successful short-term investing, highlighting the use of a specific screening strategy to find stocks with strong fundamentals and positive price momentum [1][2][3]. Group 1: Stock Performance - BioLife Solutions, Inc. (BLFS) has shown a solid price increase of 16.5% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also maintained a price increase of 3.7% over the last four weeks, suggesting that the upward trend is still intact [5]. - BLFS is currently trading at 90.3% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - BLFS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. - The Zacks Rank system has a proven track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988, underscoring the reliability of this ranking system [7]. Group 3: Investment Strategy - The article suggests that investors should consider other stocks that pass the "Recent Price Strength" screen, which identifies stocks with strong fundamentals and positive price trends [8]. - The Zacks Research Wizard tool is recommended for backtesting stock-picking strategies, allowing investors to evaluate the effectiveness of their approaches [9].

Core Insights - BioLife Solutions reported a 7% sequential increase in fourth quarter Cell Processing revenue, reaching $20.3 million, and a full year revenue of $73.5 million, exceeding the high end of previously raised guidance [1][2][8] - The company experienced its fifth consecutive quarter of sequential revenue growth in the Cell Processing platform, indicating strong operational execution and strategic focus [2][8] - The divestiture of its freezer and biostorage businesses has streamlined operations, allowing BioLife to concentrate on its core competencies in the cell and gene therapy market [2][4] Financial Performance - Preliminary unaudited revenue for the fourth quarter of 2024 was $22.7 million, a 31% increase from $17.4 million in the same quarter of 2023 [8] - For the full year 2024, total revenue was $82.3 million, reflecting an 8% increase from $75.9 million in 2023 [8] - The Cell Processing platform revenue for 2024 was $73.5 million, up 12% from the previous year, while the Evo and Thaw platform revenue decreased by 14% to $8.7 million [8] Strategic Focus - The company emphasizes its role in biopreservation solutions, which are embedded in 17 approved therapies, highlighting its importance in enabling lifesaving therapies [2] - Looking ahead to 2025, BioLife aims to leverage its strong balance sheet and core business momentum to achieve sustainable growth and profitability [2]

BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected ...

Completes the Company's strategic move away from capital equipment businessesBOTHELL, Wash., Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash."We have now completed the divestiture of all our freeze ...

Financial Data and Key Metrics Changes - BioLife Solutions reported Q3 2024 revenue from continuing operations of $30.6 million, a 30% increase year-over-year, primarily driven by a 43% increase in cell processing platform revenue [20][21] - Adjusted gross margin for Q3 2024 was 54%, up from 44% in the prior year, while GAAP gross margin increased to 51% from 48% [21][25] - Adjusted EBITDA for Q3 2024 was $6.1 million, or 20% of revenue, compared to $1.4 million, or 6% of revenue, in the prior year [26][25] Business Line Data and Key Metrics Changes - Cell Processing platform revenue totaled $19 million, reflecting a sequential increase of 6% and a year-over-year increase of 43% [8][20] - Biopreservation media products, which account for the majority of cell processing revenue, showed strong quarter-over-quarter growth, although there was a decline in other products due to timing [12][20] Market Data and Key Metrics Changes - The top 20 customers accounted for approximately 80% of biopreservation media revenue, with 60% of this revenue coming from direct customers, and 40% from customers with approved therapies [12][20] - BioLife's biopreservation media products are embedded in over 70% of relevant, commercially sponsored CGT clinical trials, indicating strong future growth potential [13] Company Strategy and Development Direction - The company announced the strategic divestiture of its SciSafe bio storage business for $73 million, marking a pivotal step towards becoming a pure-play CGT tools provider [10][14] - Future focus will be on high-growth, high-margin cell processing products, with plans to allocate capital towards expanding the biopreservation media product line [14][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the improving macro environment for the bioproduction subsector, highlighting four consecutive quarters of sequential revenue growth [7][11] - The company anticipates continued growth in 2025, with destocking issues largely behind them [36][52] Other Important Information - The company updated its 2024 revenue guidance to $98 million to $100 million, reflecting an increase in cell processing platform guidance offset by a decrease in expected storage revenue due to the sale of SciSafe [31][32] - Cash and marketable securities balance as of September 30, 2024, was $39.3 million, an increase from $36.9 million as of June 30, 2024 [29] Q&A Session Summary Question: Can you frame up what pro forma gross margins look like post SciSafe sale? - The adjusted gross margin without SciSafe for the first half of 2024 was 60%, with minimal impact expected on adjusted EBITDA profile going forward [34] Question: How should we think about long-term growth from here? - Management indicated that formal guidance for 2025 will be provided in early January, but they expect growth to continue [36] Question: What will be the focus post SciSafe sale? - The focus will be on the cell processing product line, particularly biopreservation media and Sexton tools, with potential for capacity expansion [38][39] Question: Can you expand on specific levers within the cell processing platform for growth? - Key factors include deepening relationships with distributors, pricing opportunities, and cross-selling Sexton tool products [47][48] Question: How is the demand from smaller customers and academia? - Demand from smaller customers is improving, with good sequential growth observed from distributors representing these segments [58] Question: What is the relevance of Asia for long-term growth? - Less than 5% of revenue comes from China, indicating that while Asia is important, it is not material for immediate growth [59]

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 77.78%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.06, delivering a surprise of 57.14%.Over the last four quarters, the company has ...

Table of Contents ____________________________________________________ Title of each class Trading symbol Name of exchange on which registered Common stock, par value $0.001 per share BLFS The NASDAQ Stock Market, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ____________________________________________________ FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT P ...

3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Third Quarter 2024 Financial Results Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 ...

Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54%GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20%Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestitureConference call begins at 4:30 p.m. Eastern time todayBOTH ...